Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antihypertensive efficacy and tolerability of low-dose perindopril/indapamide combination compared with losartan in the treatment of essential hypertension
Autore:
Chanudet, X; De Champvallins, M;
Indirizzi:
Hop Begin, Dept Cardiovasc Pathol, F-94160 St Mande, France Hop Begin St Mande France F-94160 ovasc Pathol, F-94160 St Mande, France Lariboisiere Hosp, Paris, France Lariboisiere Hosp Paris FranceLariboisiere Hosp, Paris, France
Titolo Testata:
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
fascicolo: 4, volume: 55, anno: 2001,
pagine: 233 - 239
SICI:
1368-5031(200105)55:4<233:AEATOL>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
AMBULATORY BLOOD-PRESSURE; ISOLATED SYSTOLIC HYPERTENSION; CIRCADIAN VARIATION; CARDIOVASCULAR RISK; OLDER PATIENTS; DOUBLE-BLIND; THERAPY; POPULATION; PLACEBO; PHARMACOLOGY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Chanudet, X Hop Begin, Dept Cardiovasc Pathol, 69 Ave Paris, F-94160 St Mande, France Hop Begin 69 Ave Paris St Mande France F-94160 Mande, France
Citazione:
X. Chanudet e M. De Champvallins, "Antihypertensive efficacy and tolerability of low-dose perindopril/indapamide combination compared with losartan in the treatment of essential hypertension", INT J CL PR, 55(4), 2001, pp. 233-239

Abstract

The aim of the study was to evaluate the antihypertensive efficacy and tolerability of the low-dose combination of the angiotensin-converting enzyme inhibitor perindopril 2 mg plus the diuretic indapamide 0.625 mg (P/I) compared with the angiotensin II antagonist losartan 50 mg (L50) in the treatment of essential hypertension. Patients (n=277) were randomised, double-blind and allocated to receive either PII or L50 once daily for a period of 12 weeks. Responder and normalisation rates in the two groups were compared bya chi(2) test. Ambulatory blood pressure monitoring results were compared using the one-tailed Student's t-test. Normalisation rates were significantly greater in the P/I group (76.0%) than in the L50 group (60.0%) (p=0.009). Responder rates were significantly higher in the PII group (91.7%) than in the L50 group (81.8%) (p=0.025), The average blood pressure reductions were: in sSBP (P/I-L50 = -2.4 mmHg; Cl: 6.2; 1.3) and sDBP (P/I-L50 = -2.0 mmHg; Cl: -4.2; 0.2), The average night-time SEP decrease (ABPM) was significantly greater in the PII group (p=0.041). The tolerability was comparable between the two groups in terms of emergent adverse events related to treatment (12.4% for P/I patients and 8.4% for L50 patients). Laboratory evaluations did not show any significant variations. It was concluded the low-dose P/I combination had significantly higher responder and normalisation rates than L50. This study also confirmed the good tolerability of both treatments.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 09:25:12